The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Open accessAbstract
Purpose: Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs of myocardial damage. Patients and Methods: In this observational, single-center study, all patients intended for TKI treatment were analyzed for coronary artery disease (CAD) risk factors, history or evidence of CAD, hypertension, rhythm disturbances, and heart failure. Monitoring included assessment of symptoms, ECGs, and biochemical markers (ie, creatine kinase-MB, troponin T). Echocardiography was performed at baseline in selected patients and in all patients who experienced a cardiac event. A cardiac event was defined as the occurrence of increased enzymes if normal at baseline, symptomatic arrhythmia that required treatment, new left ventricular dysfunction, or acute coronary syndrome. Results: A total of 86 patients were treated with either sunitinib or sorafenib. Among 74 eligible patients, 33.8% experienced a cardiac event, 40.5% had ECG changes, and 18% were symptomatic. Seven patients (9.4%) were seriously compromised and required intermediate care and/or intensive care admission. All patients recovered after cardiovascular management (ie, medication, coronary angiography, pacemaker implantation, heart surgery) and were considered eligible for TKI continuation. Statistically, there was no significant survival difference between patients who experienced a cardiac event and those who did not experience a cardiac event. Conclusion: Our observations indicate that cardiac damage from TKI treatment is a largely underestimated phenomenon but is manageable if patients have careful cardiovascular monitoring and cardiac treatment at the first signs of myocardial damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Cited by
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
“Because of the concern for asymptomatic-reduced LVEF and the potential to aggravate this finding, resulting in symptomatic HF, it is suggested that a cardiologist (preferably a cardio-oncology specialist) participate in the care of these patients.(146,149) A thorough evaluation should be done and coordination of medic…”
BackgroundMethodInfluentialA population-based study of cardiovascular disease mortality risk in US cancer patients
Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 923
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1920 · Cited by 815
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21341 · Cited by 723
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 531
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Cardiotoxicity of Anthracyclines
Cardinale, D., Iacopo, F., & Cipolla, C. M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00026 · Cited by 463
Choueiri, T. K., Schutz, F. A. B., Je, Y., Rosenberg, J. E., & Bellmunt, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2757 · Cited by 434
Cardiotoxicity of anticancer treatments
Ewer, M. S., & Ewer, S. M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.65 · Cited by 415
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J.-B., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J., Liu, G., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 410
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404
Bovelli, D., Plataniotis, G., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq200 · Cited by 401
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2017 · Cited by 357
Erratum: Cardiotoxicity of anticancer treatments
Ewer, M. S., & Ewer, S. M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.133 · Cited by 340
Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K. (2016) · Circulation · doi:10.1161/circulationaha.115.018347 · Cited by 329
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Choueiri, T. K., Mayer, E. L., Je, Y., Rosenberg, J. E., Nguyen, P. L., Azzi, G. R., Bellmunt, J., Burstein, H. J., & Schutz, F. A. B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9129 · Cited by 293
Cardiotoxicity induced by tyrosine kinase inhibitors
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009) · Acta Oncologica · doi:10.1080/02841860903229124 · Cited by 284
Ranpura, V., Hapani, S., Chuang, J., & Wu, S. (2010) · Acta Oncologica · doi:10.3109/02841860903524396 · Cited by 276
Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Hahn, V. S., Lenihan, D. J., & Ky, B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000665 · Cited by 264
Hypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., et al. (2019) · Blood · doi:10.1182/blood.2019000840 · Cited by 260
Cardiovascular disease in cancer survivors
Okwuosa, T. M., Anzevino, S., & Rao, R. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134417 · Cited by 97
Mughal, T. (2010) · Biologics: Targets & Therapy · doi:10.2147/btt.s5775 · Cited by 53
Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires
Conant, G., Ahadian, S., Zhao, Y., & Radisic, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12048-5 · Cited by 25
Twarog, N. R., Low, J. A., Currier, D. G., Miller, G., Chen, T., & Shelat, A. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149439 · Cited by 16
Metadata
- Authors
- Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-11-10
- Volume
- 26
- Issue
- 32
- Pages
- 5204-5212
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164802689
- Cited by
- 615
- References
- 27
- FWCI
- 37.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.